Irofulven demonstrates clinical activity against metastatic hormone-refractory prostate cancer in a phase 2 single-agent trial

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 28, Issue 1, 2005, Pages 36-42

  Senzer, Neil ^a,f   Arsenau, James ^b   Richards, Donald ^c   Berman, Barry ^d   MacDonald, John R ^e   Smith, Sheri ^e  

^a TEXAS ONCOLOGY   (United States)

^b Albany Regional Cancer Center   (United States)

^c Tyler Cancer Center   (United States)

^d Cancer Centers of Florida   (United States)

^e GUILFORD PHARMACEUTICALS INC   (United States)

^f BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

6 hydroxymethylacylfulvene; Chemotherapy; Irofulven; MGI 114; Prostate cancer

Indexed keywords

6 HYDROXYMETHYLACYLFULVENE; ANTIEMETIC AGENT; CYTOTOXIC AGENT; DEXAMETHASONE; ERYTHROPOIETIN; GLUCOCORTICOID; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PHYTOMENADIONE; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 11; SEROTONIN 3 ANTAGONIST; STEROID;

ADULT; AGED; ANEMIA; ANTIGEN DETECTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BLOOD TOXICITY; BLOOD TRANSFUSION; BONE PAIN; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPLOPIA; DISEASE ACTIVITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FATIGUE; HUMAN; INFECTION; INFECTION RISK; KIDNEY FAILURE; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PROSTATE ADENOCARCINOMA; PROTEIN BLOOD LEVEL; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; VISUAL IMPAIRMENT;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SESQUITERPENES; SURVIVAL ANALYSIS;

EID: 13444303832     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.coc.0000139019.17349.ed     Document Type: Article

References (30)

1. American Cancer Society. Cancer Facts & Figures 2003. New York: American Cancer Society, Inc; 2003.
2. Harris KA, Reese DM. Treatment options in hormone-refractory prostate cancer: current and future approaches. Drugs. 2001;61:2177-2192.
3. Edelman MJ, Meyers FJ, Grennan T, et al. Phase II trial of pyrazine diazohydroxide in androgen-independent prostate cancer. Invest New Drugs. 1998;16:179-182.
4. Small EJ, Fippin LJ, Whisenant SP. Pyrazoloacridine for the treatment of hormone-refractory prostate cancer. Cancer Invest. 1998;16:456-461.
5. Malkowicz SB. The role of diethylstilbestrol in the treatment of prostate cancer. Urology. 2001;58:108-113.
6. Small EJ. Docetaxel in prostate cancer. Anticancer Drugs. 2001;12:S17-20.
7. Dowling AJ, Panzarella T, Ernst DS, et al. A retrospective analysis of the relationship between changes in serum PSA, palliative response and survival following systemic treatment in a Canadian randomized trial for symptomatic hormone-refractory prostate cancer. Ann Oncol. 2001;12:773-778.
8. MacDonald JR, Muscoplat CC, Dexter DL, et al. Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S. Cancer Res. 1997;57:279-283.
9. Kelner MJ, McMorris TC, Montoya M, et al. Characterization of MGI 114 (HMAF) histiospecific toxicity in human tumor cell lines. Cancer Chemother Pharmacol. 1999;44:235-240.
10. Woynarowska BA, Roberts K, Woynarowski JM, et al. Targeting apoptosis by hydroxymethylacylfulvene in combination with gamma radiation in prostate tumor cells. Radiat Res. 2000;154:429-438.
11. Izbicka E, Davidson K, Lawrence R, et al. Cytotoxic effects of MGI 114 are independent of tumor p53 or p21 expression. Anticancer Res. 1999;19:1299-1307.
12. Kelner MJ, McMorris TC, Estes L, et al. Efficacy of MGI 114 (6-hydroxymethylacylfulvene, HMAF) against the mdr1/gp170 metastatic MV522 lung carcinoma xenograft. Eur J Cancer. 1998;34:908-913.
13. Boehme M, Stringer S, Weitman S, et al. Antitumor activity of irofulven (MGI 114) in combination with Taxotere against DU-145 human prostate xenograft model [Abstract]. Proc AACR. 2001;42:88.Abstract 475.
14. Eckhardt SG, Baker SD, Britten CD, et al. A Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks. J Clin Oncol. 2000;18:4086-4097.
15. Fleming TR. One sample multiple testing procedure for phase II clinical trials. Biometrics. 1982;38:143-151.
16. Millikan RE. Chemotherapy of advanced prostatic carcinoma. Semin Oncol. 1999;26:185-191.
17. Roth BJ, Yeap BY, Wilding G, et al. Taxol in advanced hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group. Cancer. 1993;72:2457-2460.
18. Morant R, Ackermann D, Trinkler F, et al. Gemcitabine in hormone refractory metastatic prostatic carcinoma - a phase II study of SAKK [Abstract]. Proc Am Soc Clin Oncol. 1997;16:311a.Abstract 1109.
19. Caty A, Oudard S, Humblet Y, et al. Phase II study of vinorelbine in patients with hormone refractory prostate cancer [Abstract]. Ann Oncol. 2001;12:847-852.
20. Hussain M, Pienta KJ, Redman BG, et al. Oral etoposide in the treatment of hormone-refractory prostate cancer. Cancer. 1994;74:100-103.
21. Canobbio L, Guarneri D, Miglietta L, et al. Carboplatin in advanced hormone refractory prostatic cancer patients. Eur J Cancer. 1993;29A:2094-2096.
22. Junoi WF, Hanselmann S, Schmitz SF, et al. Carboplatin in advanced hormone refractory prostate cancer [Abstract]. Proc Am Soc Clin Oncol. 1995;14:A616.Abstract 616.
23. Hamilton A, Muggia F. Estramustrine potentiates taxane in prostate and refractory breast cancers. Oncology (Huntingt). 2001;15:40-43.
24. Picus J, Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol. 1999;26:14-18.
25. Petrylak DP. Docetaxel (Taxotere) in hormone-refractory prostate cancer. Semin Oncol. 2000;27:24-29.
26. Woynarowska BA, Higdon AL, Munoz RM, et al. Changes in prostate-specific antigen (PSA) level correlate with growth inhibition of prostate cancer cells treated in vitro with a novel anticancer drug, irofulven. Invest New Drug. 2001;19:283-291.
27. Culine S, Tombal B, Pozzo C, et al. Randomized phase II trial of irofulven with or without prednisone in hormone-refractory prostate cancer (HRPC) patients (pts): preliminary results [Abstract]. Proc Am Soc Clin Oncol. 2002;21;161b. Abstract 2462.
28. Barrera H, MacDonald JR, Hilsenbeck S, et al. In vitro antitumor activity of MGI 114 in combination with topotecan, Taxol, cisplatin, etoposide, or gemcitabine against pediatric tumor cell lines [Abstract]. Proc AACR. 1998;39:527. Abstract 3585.
29. Britten CD, Hilsenbeck SG, Eckhardt SG, et al. Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model. Cancer Res. 1999;59:1049-1053.
30. Hammond LA, Hilsenbeck SG, Eckhardt SG, et al. Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV 522 lung carcinoma xenograft model. Eur J Cancer. 2000;36:2430-2436.